You are here

Share:

Biomarkers for cancer patients treated with cancer vaccines

Summary
The National Cancer Institute’s Chemical Biology Laboratory seeks parties to license or co-develop a diagnostic tool that identifies serum biomarkers of cancer targeting carbohydrate antigens.
NIH Reference Number
E-234-2010
Product Type
Keywords
  • Carbohydrate
  • Glycan
  • Glycoprotein
  • Antigen
  • Vaccine
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Although antibodies are a critical element of the immune response, the role of antibody responses in cancer vaccines is still unknown.  Carbohydrate antigens, which are directly or indirectly involved in most types of cancer vaccines, are a class of antigens that has been largely understudied but play a significant role in the immune response of cancer vaccines.

This invention involves the identification of serum biomarkers for cancer that target carbohydrate antigens. The biomarkers are specific sub-populations of serum antibodies present in the serum of patients that bind to various glycan and/or glycoprotein antigens, such as the Forssman antigen. This technology can be developed into a pioneering test, as no such test to monitor prognosis and efficacy of cancer vaccines currently exists in the market.

Clinical data has been obtained; validation studies are ongoing, preliminary results confirmed in two independent patient groups.

Potential Commercial Applications
  • Diagnostic and prognostic test to monitor the progression and long-term survival of cancer patients
  • Predictive indicator of cancer patient's immune response to a cancer vaccine
  • Indicator to monitor the efficacy of a cancer vaccine
Competitive Advantages
  • First diagnostic tool of its kind to monitor prognosis and efficacy of cancer vaccines.
Development Stage
Publications

Gildersleeve JC, et al. [PMID: 23063402]

Patent Status
  • Foreign Filed: Australian - Patent Application
  • Foreign Issued: EP - Patent Number 11749629.9
Therapeutic Area
Updated
Wednesday, December 20, 2017